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Background: Tumor cell migration and metastasis require dynamic rearrangements of the actin cytoskeleton.
Interestingly, the F-actin cross-linking and stabilizing protein L-plastin, originally described as a leukocyte specific
protein, is aberrantly expressed in several non-hematopoietic malignant tumors. Therefore, it has been discussed as
a tumor marker. However, systematic in vivo analyses of the functional relevance of L-plastin for tumor cell
metastasis were so far lacking.
Methods: We investigated the relevance of L-plastin expression and phosphorylation by ectopical expression of
L-plastin in human melanoma cells (MV3) and knock-down of endogenous L-plastin in prostate cancer (PC3M). The
growth and metastatic potential of tumor cells expressing no L-plastin, phosphorylatable or non-phosphorylatable
L-plastin was analyzed in a preclinical mouse model after subcutaneous and intracardial injection of the tumor cells.
Results: Knock-down of endogenous L-plastin in human prostate carcinoma cells led to reduced tumor cell growth
and metastasis. Vice versa, and in line with these findings, ectopic expression of L-plastin in L-plastin negative
melanoma cells significantly increased the number of metastases. Strikingly, the metastasis promoting effect of
L-plastin was not observed if a non-phosphorylatable L-plastin mutant was expressed.
Conclusions: Our data provide the first in vivo evidence that expression of L-plastin promotes tumor metastasis
and, importantly, that this effect depends on an additionally required phosphorylation of L-plastin. In conclusion,
these findings imply that for determining the importance of tumor-associated proteins like L-plastin a
characterization of posttranslational modifications is indispensable.
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Development of metastasis causes the most serious clin-
ical consequences of cancer and is responsible for over
90% of cancer related deaths [1]. The process of metastasis
is complex. It involves release of tumor cells from the pri-
mary tumor, intravasation, dissemination within vessels,
adhesion to vessel walls, extravasation as well as invasion
and migration into the tissue of distant organs in order to
colonize and form metastases. These steps require a high* Correspondence: Yvonne.Samstag@urz.uni-heidelberg.de
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reproduction in any medium, provided the ormotility of cancer cells, which is mediated by modulation
of the cellular cytoskeleton (for review see [2,3]). Recent
studies indicate cytoskeleton binding proteins as import-
ant players in tumor metastasis [4,5] (for review see [6]),
particularly by their capability to bind to and regulate
integrin molecules [7]. Therefore, such molecules may
be promising targets to inhibit the metastatic properties
of tumor cells.
Interestingly, some cancers express the actin reorganiz-
ing protein L-plastin, which is normally leukocyte specific
and not present in non-hematopoietic cells [8,9]. After the
discovery of L-plastin as a tumor-associated protein, itsal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, results of clinical studies comparing L-plastin
expression in tumor specimen from patients with dis-
ease severity were ambiguous (for review see [12]). While
expression of L-plastin correlated with the invasive po-
tential of colorectal cancer [13], there was no correlation
between L-plastin expression and tumor progression in
breast cancer [14] or melanoma [15]. One reason for this
discrepancy may be that these studies did not consider the
phosphorylation status of L-plastin.
The plastin family of actin-binding proteins consists of
three isoforms, which show tissue specific expression.
They exhibit a similar molecular organization containing
two consecutive actin binding domains in the C-terminus,
each consisting of two calponin homology (CH)-domains.
This structure allows the organization of actin filaments
into very tight bundles. In the N-terminal part there are
two helix-loop-helix EF-hand Ca2+-binding motifs as well
as a phosphorylation site on Ser5 (for review see [16]).
Ser5 phosphorylation was shown to increase the actin
bundling activity of L-plastin in vitro to promote its target-
ing to sites of actin assembly [17]. Regulation through
phosphorylation of L-plastin has been described as a
consequence of immune responses [18-20] as well as in
response to signals triggering migration [21].
L-plastin function is important for cells of the innate
as well as the adaptive immune system. We have dem-
onstrated that L-plastin is crucial for immune synapse for-
mation [19]. Furthermore, it regulates integrin-dependent
adhesion and migration of both granulocytes [22,23] and
T-cells [24]. From in vitro studies there were also hints
that L-plastin plays a role in tumor cell motility (for review
see [12,25,26]). However, so far no in vivo experiments
existed investigating whether L-plastin plays a crucial role
for tumor cell metastasis.
Therefore, in this study we systematically analyzed the
in vivo role of L-plastin expression as well as L-plastin
phosphorylation for tumor cell growth and tumor metas-
tasis formation in a xenograft mouse model after sub-
cutaneous or intracardial injection respectively of different
human cancer cells.
Results
Knock-down of L-plastin in human prostate cancer cells
reduces tumor growth in vivo
To investigate the effect of endogenous L-plastin expres-
sion on tumor cell behaviour, the L-plastin positive human
prostate cancer cell line PC-3Mpro4/luc was used (in the
following designated as PC3M). These PC3M cells, in
addition, stably express luciferase and thus, exhibit lumi-
nescence in the presence of luciferin (Additional file 1:
Figure S1A, upper two panels). L-plastin was phosphoryla-
table in these cells since PMA (phorbol 12-myristate 13-
acetate) stimulation of PC3M cells led to phosphorylationof the endogenous L-plastin, as detected by an anti-
phospho Ser5 L-plastin antibody (Figure 1A). To reduce
L-plastin expression in PC3M cells we used a lentiviral
system to deliver an L-plastin specific shRNA. In parallel a
non-targeting shRNA was expressed. As illustrated in
Figure 1B, treatment with L-plastin specific shRNA (LPL
shRNA) resulted in an over 90% reduction in L-plastin
protein expression in contrast to cells treated with non-
targeting control shRNA (nt shRNA) or untreated PC3M
(PC3M untreated). Note that bioluminescent activity was
not influenced by shRNA transfection (Additional file 1:
Figure S1A, lower two panels).
Contact dependent as well as anchorage independent
cell growth was then analyzed in vitro. For contact
dependent proliferation, cell growth on tissue culture
plates was counted daily up to 96 hours (Figure 1C). The
knock-down of L-plastin had no effect on proliferation in
this system. Anchorage independent proliferation was de-
termined with a soft agar assay [27]. This assay did also
not unravel a growth disadvantage of PC3M cells due to a
knock-down of L-plastin (Figure 1D). Together, knock-
down of L-plastin had no effect on in vitro proliferation.
We next analyzed the in vivo tumor growth in a
xenograft mouse model. PC3M cells either containing en-
dogenous L-plastin, or PC3M cells expressing nt shRNA
or the LPL shRNA were injected subcutaneously in the
left leg of nude mice. These mice lack a thymus and are
not able to induce an adaptive immune response against
human cells [28]. Tumor growth was analyzed weekly
over 42 days. Primary tumors were excised at day 42
and tumor volume was calculated. Surprisingly, knock-
down of L-plastin reduced significantly the primary tumor
growth in vivo (Figure 1E and F). Since the in vitro prolif-
eration was not significantly changed by knock-down of
L-plastin, this diminished tumor growth could be due to a
malfunction in colonialization.
Knock-down of L-plastin interferes with processes crucial
for colonialization of tumor cells
In order to spread and colonize adjacent or non-adjacent
tissues or organs, cancer cells need to migrate through the
body. To investigate whether endogenous L-plastin expres-
sion in human tumor cells facilitates this process, we first
analyzed the migratory potential of PC3M cells in vitro in
transwell assays. Tumor cell metastasis is strongly influ-
enced by stimuli, like chemokines or integrins, surrounding
the tumor cells [29]. Since L-plastin promotes integrin-
mediated adhesion and migration of hematopoietic cells
[16], we determined migration with the integrin ligand col-
lagen I as a substrate and an additional chemoattractant
(SDF1α) in the lower chamber of the transwell system (for
details see Material and methods). Indeed, the knock-down
of L-plastin in PC3M cells (PC3M LPL shRNA) signifi-
cantly reduced migration (Figure 2).
Figure 1 (See legend on next page.)
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Figure 1 L-plastin knock-down in prostate carcinoma cells. (A) L-plastin is expressed in PC3M cells and gets phosphorylated following PMA
stimulation. Phosphorylation of L-plastin in untreated PC3M or PC3M preincubated with 10-8 M PMA for 30 min was determined by Western blot
with a phospho-Ser5 L-plastin specific antibody (upper panel). Total expression of L-plastin (lower panel). (B) ShRNA mediated downregulation of
L-plastin in PC3M. PC3M infected with lentivirus encoding L-plastin (LPL) or non-targeting (nt) shRNA were analysed by Western blot for LPL
protein (upper part), and β-actin as loading control. Quantification by densitometry of three independent experiments is shown in the lower part.
For each experiment L-plastin levels were normalized for β-actin. The amount of L-plastin in untreated PC3M was set as 100%. Results were
analyzed using one-way ANOVA (n = 3) (* = p < 0,05). (C) No influence of L-plastin knock-down on contact dependent in vitro proliferation of
PC3M. Data represent means ± SEM, experiments were repeated at least 3 times with samples in triplicate. (D) Unchanged anchorage
independent in vitro proliferation of L-plastin knock-down PC3M. PC3M (as indicated) were allowed to grow in soft agar for 21 days. Cell culture
plates with the colonies were scanned using a transmission light scanner (upper panel). Single colonies were acquired with a 20x objective
(lower panel). Bars indicate the colony numbers in three optical fields. Data represent means ± SEM. Results were analyzed using one-way ANOVA
(n = 4; ns = not significant). (E/F) Knock-down of L-plastin in PC3M leads to reduced tumor volumes in vivo. PC3M (as indicated) were injected
subcutaneously into mice. (E) Representative images of excised tumors at day 42. (F) Tumor volumes calculated weekly (n = 10; *p < 0.05 for
PC3M vs. PC3M LPL shRNA and PC3M nt shRNA vs. PC3M LPL shRNA).
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xenograft mouse model is reduced by knock-down of
L-plastin
The experiments shown in Figure 2 suggest a function
of L-plastin in the process of cancer cell spreading and
induction of metastatic colonies. In the so far here used
experimental model of subcutaneous tumor cell injection
no spontaneous metastasis to non-adjacent organs was de-
tected. Therefore, we switched to an established metastasis
model involving intracardial injection of tumor cells in
nude mice [30], to analyze whether L-plastin promotes
tumor metastasis. After injection of either PC3M cells
containing endogenous L-plastin or L-plastin knock-down
PC3M cells (PC3 LPL shRNA) into the left cardiac ven-
tricle of nude mice, the number of metastatic colonies
was assessed by weekly ventral and dorsal biolumines-
cence imaging of mice and counting of luciferase-positive
foci from both sides. Figure 3A shows dorsal images of
day 7, 21 and 42. Indeed, L-plastin knock-down PC3M
cells showed significantly reduced numbers of metastatic
colonies in the animals over a period of 42 days compared
to animals injected with nt shRNA transfected PC3M or
untransfected PC3M cells (Figure 3A and B). These dataFigure 2 L-plastin knock-down reduces cancer cell migration in vitro.
collagen I of PC3M nt shRNA and PC3M LPL shRNA cells was analyzed as d
for migration assays. Results were analyzed using student’s t-test, data repredemonstrate that L-plastin expression promotes tumor
metastasis by enhancing colonialization.
Ectopically expressed wildtype L-plastin undergoes
spontaneous phosphorylation on Ser5 in melanoma cells
For an independent confirmation that L-plastin plays a
role in in vivo colonialization of tumor cells the human
melanoma cell line MV3 was used, since these cells were
negative for endogenous L-plastin expression. This gives
the possibility to analyze the effect of L-plastin on metas-
tasis even in a phosphorylation-dependent manner via a
transfection of wildtype or non-phosphorylatable L-plastin
into these melanoma cells. To allow in vivo imaging of
tumor cells, first, a cDNA encoding the luciferase 2 gene
(pCAGG3.1-luc2) was transfected in MV3 cells and
luciferase 2 expressing cells (designated as MV3) were
selected, cloned and tested for their bioluminescence
activity as well as for their proliferative and migratory
capability. Luciferase expression had no influence on
proliferation and migration of the cells (data not shown).
Cells with a stable and strong bioluminescence activity
(Figure 4A) were chosen for further transfections to gener-
ate stable L-plastin expressing clones.SDF1α (350 ng/ml) mediated migration towards the integrin ligand
escribed in material and methods. Cells were incubated for 18 hours
sent means ± SEM (n≥ 3; * = p < 0.05).
Figure 3 L-plastin knock-down reduces metastasis of prostate carcinoma cells. Tumor metastasis monitored by in vivo bioluminescence
imaging. (A) Representative examples of dorsal optical images of mice injected with PC3M, PC3M nt shRNA or PC3M LPL shRNA cells at the
indicated time points are shown. (B) Quantification of metastasis. Numbers of single spots, representing metastatic lesions, were counted from a
ventral and dorsal view per animal and plotted over time after cancer cell injection. Results were analyzed using student’s t-test, data represent
means ± SEM (n = 12 for PC3M and PC3M nt shRNA; n = 17 for PC3M LPL shRNA; * = p < 0.05 for PC3M vs. PC3M LPL shRNA and PC3M nt shRNA
vs. PC3M LPL shRNA).
Figure 4 Phosphorylation of L-plastin in melanoma cells occurs spontaneously at Ser5. (A) Bioluminescence imaging of MV3
pCAGG3.1luc2 clone 2 (MV3) cells in vitro. The color bar on the right indicates the signal intensity range (p/s/cm2/sr). (B) Western blot analysis of
L-plastin levels in different MV3 cells: untransfected MV3 cells (MV3), MV3 cells transfected with a control vector (MV3 control), or MV3 cells
expressing either LPL (MV3 LPL) or S5A LPL (MV3 S5A LPL). (C) L-plastin phosphorylation, detected via a phospho Ser5 L-plastin antibody in
Western Blot, occurs in MV3 cells expressing WT LPL plus and minus PMA stimulation but not in MV3 cells expressing S5A LPL. (D) Proliferation of
the different MV3 cells in vitro. Data represent means ± SEM, experiments were repeated at least three times with samples in triplicates.
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in melanoma cells was not determined. From our previ-
ous work we know, that a S5AS7A mutant of L-plastin
prevents phosphorylation [15]. In leukocytes and Vero
cells Ser5 was identified as the site of phosphorylation
[17,18,22,31]. To investigate if Ser5 is also the crucial
site of phosphorylation in melanoma cells, a cDNA en-
coding wildtype L-plastin (LPL) or a mutated version of
L-plastin (S5A LPL) were transfected into MV3 cells.
Immunoblot analysis of generated cell clones revealed
no expression of L-plastin in untransfected cells or cells
transfected with a vector control (MV3 control), but high
L-plastin expression was found in MV3 LPL and MV3
S5A LPL cells (Figure 4B). Note that the bioluminescent
activity was not influenced by transfection or L-plastin
expression (Additional file 1: Figure S1B). Interestingly,
the wildtype L-plastin is already partially phosphorylated
in the absence of further external stimuli. After stimula-
tion of these cells with the phorbol ester PMA, the
amount of phosphorylated L-plastin was enhanced as
observed for the PC3 cells. These findings, in addition,
imply that a protein kinase C is involved in the phosphor-
ylation of L-plastin in these tumor cells. Such an L-plastin
phosphorylation was, however, only observed in wild-
type L-plastin expressing cells. In contrast, S5A mutation
within the L-plastin molecule prevented phosphorylationFigure 5 L-plastin phosphorylation is important for migration and inv
(B) absence of collagen I and (C) invasion into matrigel of MV3, MV3 contr
analyzed using 10% FCS as chemoattractant as described in materials and
hours for invasion assays. Left part: representative confocal laser scan micro
independent experiments were calculated using one-way ANOVA, values reas detected with a specific anti phospho Ser5 L-plastin
antibody (Figure 4C) or in an assay analyzing total
L-plastin phosphorylation (Additional file 2: Figure S2).
Together, these data suggest that Ser5 is the functional
relevant phosphorylation site of L-plastin for melanoma
cell colonialization in vivo. In line with the data obtained
with PC3M cells, expression of L-plastin had no effect on
tumor cell proliferation in vitro (Figure 4D).
L-plastin phosphorylation on Ser5 is required for the
promoting effect of L-plastin on tumor cell migration
in vitro
Following the biochemical proof that mutation at Ser5 to
alanine prevents phosphorylation, we next checked the
functional consequences of L-plastin phosphorylation on
Ser5 in melanoma cells. Thus, MV3 cells expressing either
wildtype or S5A L-plastin were tested for their migratory
and invasive potential in vitro. With collagen I as substrate
(Figure 5A) transwell assays showed increased migration in
the presence of wildtype L-plastin expression (MV3 LPL).
This increase in the migratory capacity was abolished, if
MV3 cells expressed only the non-phosphorylatable S5A
LPL (Figure 5A). Chemotaxis in the absence of adhesive
substrates was not influenced by either expression or phos-
phorylation of L-plastin, indicating that phosphorylation
of Ser5 in L-plastin is important for integrin-mediatedasion of tumor cells in vitro. (A) migration in the presence or
ol, MV3 LPL and MV3 S5A LPL cells. Migration and invasion were
methods. Cells were incubated 3 hours for migration assays and 18
scopy of migrated cells. Right part: statistics of at least three
present means ± SEM (* = p < 0.05; ns = not significant).
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investigated using a matrigel invasion assay [15]. Again,
expression of L-plastin increased the number of trans-
migrating cells in contrast to cells without L-plastin ex-
pression or cells expressing the S5A LPL (Figure 5C).
Thus, only expression of L-plastin phosphorylatable on
Ser5 facilitated substrate-guided migration and invasive-
ness of MV3 cells in vitro.
L-plastin enhances in vivo metastasis of human
melanoma cells in a phosphorylation dependent manner
The subsequent experiments were designed to determine
whether expression of L-plastin and its phosphorylation
on Ser5 are crucial not only for melanoma cell migration
and invasion in vitro, but also for the enhancement of
tumor cell metastasis in vivo. Indeed, expression of wild-
type L-plastin in MV3 cells led to an increased number of
metastatic colonies in mice after intracardial injection ofFigure 6 L-plastin expression enhances metastasis in a phosphorylati
monitored by bioluminescence imaging. Numbers of single spots, represen
per animal and plotted over time after cancer cell injection. Results were a
MV3 and MV3 control; n = 13 for MV3 LPL and MV3 S5A LPL; * = p < 0.05 an
ns = not significant). (B) Representative pictures of dorsal optical images ob
MV3 control, MV3 LPL and MV3 S5A LPL cells. (C) L-plastin expression and
cells. Representative immunohistochemical pictures of excised metastatic le
control, total L-plastin and phospho Ser5 L-plastin.the tumor cells (Figure 6A). In marked contrast, expres-
sion of the non-phosphorylatable L-plastin variant did not
influence cancer cell metastasis. Figure 6B shows repre-
sentative bioluminescence images on day 5, 13, 27 from all
groups. To investigate whether wildtype L-plastin is still
phosphorylated in the metastatic colonies in vivo, tumors
were excised and analyzed by immunohistochemistry
using the phospho L-plastin antibody. Figure 6C demon-
strates that phosphorylated L-plastin can be detected in
metastatic tumor cells. Together, these data demonstrate,
that ectopic expression of L-plastin in tumor cells en-
hances metastasis and that, strikingly, not only expression,
but also phosphorylation of L-plastin is important to pro-
mote tumor metastasis.
Discussion
In order to metastasize, tumor cells must be able to
leave the primary tumor and to colonize other tissues.on dependent manner. (A) Quantification of tumor metastasis
ting metastatic lesions, were counted from a ventral and dorsal view
nalyzed using student’s t-test, data represent means ± SEM (n = 12 for
d ** = p < 0.01 for MV3 LPL vs. MV3 or MV3 control or MV3 S5A LPL;
tained at the indicated time points after injection of mice with MV3,
phosphorylation in metastatic lesions of mice injected with MV3 LPL
sions of mice bearing MV3 LPL tumors. They were stained for IgG
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arrangement of the actin cytoskeleton via actin binding
proteins (for review see [6]). In contrast to untransformed
tissue cells, a variety of human tumor cells express the pri-
marily leukocyte specific protein L-plastin [9]. Yet, its cel-
lular function in vivo and its causal relationship to tumor
cell metastasis remained unclear. Thus, contradictory re-
sults regarding the correlation of L-plastin expression with
tumor progression in patients in different tumor entities
were found [13-15].
Hints for a role of L-plastin expression and its phosphor-
ylation in metastasis came from our prior experiments
showing that expression of wildtype L-plastin, but not of
its non-phosphorylatable counterpart S5AS7A L-plastin
strongly enhanced the capacity of MV3 melanoma cells to
invade into matrigel in vitro [15]. These studies gave rise
to the assumption that (i) the expression of L-plastin and
(ii) its ability to become phosphorylated may provide
tumor cells an advantage to form metastases. Our aim was
to test this hypothesis for human cancer cells in vivo by
using a xenograft mouse model. We found that expression
of L-plastin in tumor cells indeed promotes their metasta-
sis in mice. This could be demonstrated in two independ-
ent experimental systems, namely either knock-down of
endogenous L-plastin expression in human prostate car-
cinoma cells or cDNA mediated L-plastin expression in
L-plastin negative melanoma cells and subsequent injec-
tion of these cells into mice. Tumor cell dissemination
and metastatic colony formation was followed by bio-
luminescence imaging and was finally confirmed by histo-
logical analysis. Metastases occurred preferentially in
bone, which is likely in part due to the injection of the
tumor cells into the left ventricle of the heart resulting in
arterial distribution. ShRNA induced lower expression
levels of endogenous L-plastin resulted in decreased me-
tastasis. In line with this finding ectopic expression of
wildtype L-plastin raised the amount of metastatic spots
in the mice. Importantly, in contrast to wildtype L-plastin,
expression of non-phosphorylatable L-plastin (S5A LPL)
in melanoma cells did not increase their metastatic poten-
tial. These analyses demonstrate for the first time in vivo
that L-plastin expression combined with L-plastin phos-
phorylation on Ser5 promotes tumor metastasis, suggest-
ing that this combination may be an important risk factor
for cancer patients. Coming along with a higher number
of metastatic colonies due to L-plastin expression and
phosphorylation, a trend towards a prolonged survival of
the animals was observed if L-plastin was not expressed,
or if the non-phosphorylatable mutant (S5A LPL) was
expressed in the tumor cells (data not shown).
Not just the formation of metastatic colonies after in-
tracardial injection of tumor cells in mice was reduced,
but also the primary subcutaneous tumor growth was
inhibited. Considering no influence of L-plastin neitheron contact dependent nor on anchorage independent
proliferation of the tumor cells in vitro, further aspects
of the process of the outgrowth of a primary tumor
seem to be influenced, namely the adhesion and colo-
nialization of the tumor cells after injection. Adhesion,
which is next to the migration of tumor cells one of the
main steps of colonialization, is coordinated by integrins.
Mechanistically, the enhanced metastatic behaviour of
wildtype L-plastin expressing cancer cells may be also me-
diated by avidity regulation of integrins, since only migra-
tion in the presence of integrin ligands was enhanced by
expression of wildtype L-plastin. In contrast, expression of
non-phosphorylatable L-plastin did not show this effect.
The resulting hypothesis that phosphorylation of L-plastin
is crucial for its action on integrins is supported by the
fact that L-plastin-derived peptides induced activation
of αvβ3-mediated adhesion of erythroleukemia cells [23]
as well as by recent data showing that L-plastin expression
[19] and phosphorylation [20,32] regulates the accumu-
lation of the β2-integrin LFA-1 at the immune synapse
of T-cells and antigen-presenting cells. A direct inter-
action of L-plastin with β-integrins was demonstrated
for T-cells [19,20] as well as for breast (MCF-7) or pros-
tate (PC3) cancer cells [33]. Notably, in vitro, L-plastin
was found in focal adhesion sites of MV3 melanoma [15]
and Vero kidney epithelial cells [34]. For the latter it was
even demonstrated that L-plastin phosphorylation modu-
lates actin dynamics in focal adhesions. Thus, L-plastin
phosphorylation may be important for integrin-mediated
tumor cell adhesion: Firstly, via connecting integrins to
the actin cytoskeleton and thereby increasing the integrin
avidity at podosomes. Secondly, via modulating the actin
cytoskeleton within these adhesive structures, which is im-
portant for stabilizing these complexes. Interestingly, the
activity of matrix degrading enzymes, like seprase, is also
regulated by integrin clustering within invadopodia [35].
Thus, a connection between L-plastin phosphorylation
and integrin avidity regulation may explain the enhanced
metastatic behaviour of L-plastin expressing tumor cells
observed in vivo, since integrins play an important role
for tumor cell migration, extravasation and adhesion.
The identification of the integrins involved in L-plastin
mediated tumor metastasis will be the subject of further
investigations. Note, however, that the behaviour of cancer
cells in vivo is strongly influenced by the local micro-
environment. Thus, the dependence of a certain tumor on
L-plastin expression and phosphorylation as well as its
mode of function can vary in different tumor entities.
Taken together, our systematic in vivo analysis dem-
onstrates for the first time that ectopic expression of
L-plastin promotes tumor metastasis. Importantly, this
L-plastin needs to be phosphorylatable on Ser5. Failure
to take this L-plastin phosphorylation into account in
studies, aiming to find a correlation between L-plastin
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plain the non-conclusive results found in different
tumor entities of patients [13-15]. Thus, future studies
are needed to establish whether L-plastin phosphoryl-
ation on Ser5 can serve as a prognostic marker. Finally,
our results suggest tissue or tumor specific inhibition
of L-plastin phosphorylation as a potential new thera-
peutic strategy to prevent metastasis of cancer. In this
regard L-plastin has the advantage that, unlike other
actin-binding proteins, it is not expressed in untrans-
formed cells of the respective non-hematopoietic tissues.
Conclusion
In summary, we show for the first time in vivo, via a pre-
clinical mouse model, that ectopic expression of L-plastin
in tumor cells promotes metastasis. Importantly, not the
expression of L-plastin alone, but rather its additionally
required phosphorylation on Ser5, enhances metastasis.
Therefore, L-plastin phosphorylation on Ser5 may serve as
novel prognostic marker. Given that L-plastin is selectively
expressed in malignant cells – but not in untransformed
non-hematopoietic cells - targeting of L-plastin expression
or inhibition of L-plastin phosphorylation may open up
novel therapeutic strategies to prevent tumor metastasis.
Materials and methods
Cell culture
The human prostate carcinoma cell line PC-3Mpro4/luc
(in the following abbreviated as PC3M) (a generous gift of
Dr. M. Cecchini, University of Berne, Switzerland) [36]
was grown in high glucose DMEM medium supplemented
with 10% fetal calf serum (FCS), w/o L-glutamine. The hu-
man melanoma cell line MV3 (a generous gift of Dr. van
Muijen, University Hospital Nijmegen, The Netherlands)
was grown in RPMI 1640 medium supplemented with
10% FCS, 2 mM glutamine at 37°C in an humidified
atmosphere containing 5% CO2. Cell lines were tested by
genome sequencing (DSMZ, Braunschweig, Germany).
Generation of an anti phospho Ser5 L-plastin antiserum
Rabbit polyclonal anti-phospho L-plastin antiserum against
Ser5 phosphorylated L-plastin was produced by Euro-
gentec according to the Speedy 28-day program. This
antiserum was generated against an L-plastin peptide
in which Ser5 was phosphorylated. Western blotting
with the purified antiserum was performed in a dilution
of 1:2000.
Mice
BALB/c nude Mice (CAnN.Cg-Foxn1nu/Crl) were pur-
chased from Charles River and were maintained in a spe-
cific pathogen-free facility of the Heidelberg University
with controlled light/dark rhythm, temperature and
humidity in concordance with animal care regulations.Cages, bedding, food and water were all autoclaved. All
experimental procedures involving animals were approved
by the responsible agency in compliance with institutional
and German governmental requirements.
Lentivirus-mediated knock-down and generation of stable
knock-down cells
MISSION® Lentiviral Transduction Particles, containing
short hairpin (sh) RNA lentiviral vectors based on pLKO.1-
puro containing a puromycin resistance gene and targeting
five different sequences on the human L-plastin gene and a
non-targeting shRNA vector as a control, were obtained
from Sigma-Aldrich (Munich). Self-inactivating replication
incompetent viral particles containing shRNAs were ob-
tained from ImaGenes (Berlin). Infection was performed
according to the manufacturer’s instructions. The shRNA




The cDNA of wild-type (wt) full-length L-plastin and
S5A-L-plastin, which were used to clone the expression
plasmid vectors, were described before [15]. The entire
coding region of wt full-length L-plastin cDNA (LPL) and
S5A-L-plastin (S5A LPL) cDNA were amplified from L-
plastin or S5A L-plastin by polymerase chain reaction
(PCR) introducing a 5′and 3′BamHI restriction site and
inserted into BamHI digested pSELECT-hygro-mcs vector
(InvivoGen). pSELECT-hygro-mcs with an EGFP insert
served as control.
The pCAGG3.1-luc2 plasmid containing the mammalian-
codon optimized firefly luciferase 2 was used as described
elsewhere [37]. All constructs were checked by standard
DNA sequencing.
Transfections and establishment of stable protein
expression in cell populations
Plasmids expressing the firefly luciferase gene (pCAGG3.1-
luc2) and plasmids expressing either wt- or S5A-L-plastin
cDNA or EGFP were transfected into MV3 cells using
Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instructions. Stable expression of trans-
ferred luciferase gene was controlled by biolumines-
cence imaging in complete medium supplemented with
150 μg/ml D-luciferin (Synchem) by in vitro imaging
using the IVIS™ camera system (Xenogen, Alameda, CA,
USA). Bioluminescent single cell clones were amplified in
culture and tested for stable luminescence and prolifera-
tive potential in vitro.
Stable expression of transferred L-plastin genes was
checked by immunoblots. L-plastin expressing single cell
clones were amplified in culture and characterized for
stable luminescence levels, L-plastin expression as well as
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clones, respectively, were expanded and initially selected
and used for further in vitro and in vivo studies.
SDS-Polyacrylamide gel electrophoresis followed by
Western-blotting
Protein lysates from cells were obtained as previously
described [15]. Cells were washed once in ice-cold Tris-
buffered saline (TBS), lysed for 30 minutes in TKM-
buffer (50 mM Tris–HCl pH 7.5, 1% NP40, 25 mM KCl,
5 mM MgCl2, 1 mM NaVO4, 5 mM NaF, 20 μg/ml each
Leupeptin/Aprotinin) and nuclei were removed by cen-
trifugation. SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed according to standard procedures.
Proteins were blotted onto polyvinylidene difluoride (PVDF,
Immobilon-P, Merck-Millipore, Darmstadt, Germany) mem-
branes. Membranes were blocked with 10% BSA in PBS.
For protein detection the membranes were incubated
with primary antibodies for L-plastin (clone LPL4A.1,
Neomarkers) (1 μg/ml), phospho L-plastin (our own anti-
body) or ß-actin (clone A2066, Sigma-Aldrich) (1:900)
overnight at 4°C, followed by incubation with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse second-
ary antibodies (Jackson ImmunoResearch). Proteins were
visualized with ECL (Amersham-Pharmacia). Densitomet-
ric analysis was performed using a GS-800-densitometer
and “Quantitiy One” software (BioRad). L-plastin phos-
phorylation was calculated as the ratio between phospho-
protein and total protein. Data from densitometric analysis
are reported as mean ± SEM.
In vitro cell proliferation and soft agar assays
For contact dependent proliferation, cells were washed,
trypsinized and adjusted to a density of 1.5 × 104 cells/ml
in culture medium. Cells in 1 ml aliquots were seeded to
grow in 24-well plastic plates. Cell numbers were counted
at the times indicated using a Neubauer chamber.
The soft agar assays (anchorage independent prolifer-
ation) were performed by preparing a 0.5% base agar
and a 0.35% top agar with RPMI1640 and FCS (10% v/v
final concentration). The layer of 0.5% agar was poured
in 24 well plates. PC3M, PC3M nt shRNA or PC3M
LPL shRNA cells were resuspended in 0.35% top agar at
a density of 1.5 × 105 cells/ml. Cell suspensions were
poured on the top of the base layer. After solidification
the agar was overlaid with RPMI1640 plus 10% FCS and
plates were incubated at 37°C in the presence of 5%
CO2. The colonies were counted in 3 optical fields in
each sample at day 13.
In vitro migration assay
In vitro xcell migration was analyzed essentially as previ-
ously described [15], using transwell migration inserts
(PET membrane, 8 μm pore size, 6 mm diameter, BDBiosciences) coated with 20 μg/ml collagen I in 0.02 N
acetic acid at the bottom side and containing soluble
chemoattractants (600 μl of either RPMI 1640 medium
containing SDF1α (350 ng/ml) for PC3M cells, or RPMI
1640 supplemented with 10% FCS for MV3 cells) in
the lower compartment. Cells were labeled for 15 mi-
nutes at 37°C/5% CO2 with 1 μM CFDA-SE (molecular
probes) in PBS prior to performing the migration assay.
2.5 × 105 cells/ml for MV3 and 1.5 × 105 cells/ml for
PC3M were allowed to transmigrate, then filters were re-
moved and cells from the upper membrane surface were
wiped off with a cotton swab. Filters were then washed,
fixed and mounted on glass slides. Cells that had migrated
to the coated lower side of the filter were detected by con-
focal laser scan microscopy and cells in four defined op-
tical fields were counted for each filter. Time points are
indicated in the figure legends.
In vitro invasion assay
To investigate the invasiveness of tumor cells BD BioCoat
Matrigel invasion chambers were used. 200 μl of a cell
suspension at a concentration of 1 × 105 cells/ml was
added to the upper compartment and cells were allowed
to migrate to the lower compartment with 10% of FCS
as a chemoattractant. Invasive cells were counted as men-
tioned above.
Subcutaneous injection of tumor cells
5 week old male BALB/c nude mice were subcutaneously
injected with 1.5 × 105 PC3M cells in 100 μl D-PBS in the
hind leg. Subcutaneous tumor growth was determined
weekly via caliper. Tumor volume was calculated by the
formula: length × width2 × 0.5.
Intracardial injection of tumor cells
5 week old nude mice were anesthetized by intraperito-
neal injection of 120 mg/kg ketamine hydrochloride with
16 mg/kg xylazine on the day of injection. Male animals
were used for the injection of PC3M cells, female mice
were used for the injection of MV3 cells. On day 0, anes-
thetized animals were injected with 1.5 × 105 PC3M cells,
or 1 × 105 MV3 cells respectively, diluted in 100 μl D-PBS
into the left cardiac ventricle. Anesthetized animals
were placed in the IVIS100 Imaging System (Xenogen,
Alameda, CA, USA) within 60 minutes after injection
and imaged dorsally and ventrally 5 min after intraperi-
toneal injection of D-luciferin. A successful intracardial
injection was indicated on day 0 by images showing sys-
temic bioluminescence distributed throughout the body
of the mouse. Only animals with evidence of a satisfac-
tory injection continued the experiment. Assessment of
subsequent metastasis was monitored in vivo once or
twice a week, depending on the tumor model, for up to
42 days.
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Bioluminescence imaging was performed with a CCD
camera in a light-tight specimen box (IVIS100, Xenogen).
Quantification of signals was performed by the acquisi-
tion and analysis software Living Image® (Xenogen). For
in vitro imaging, bioluminescent cells were serially di-
luted from 1 × 103 to 2 × 105 cells into black 96-well
Plates. 600 μg/ml D-luciferin was added to each well
5 min before imaging. Imaging time was 1 min/plate,
Binning M. For in vivo imaging, animals were anesthetized
with isoflurane and were given D-luciferin (15 mg/ml
in D-PBS; 100 μl/10 g body weight) by intraperitoneal
injection. Mice were placed into the light-tight camera
box with continuous exposure to isoflurane. Imaging time
ranged from 10 s to 1 min, depending on the tumor
model, 5 min after D-luciferin injection. Two mice were
imaged each time from a dorsal and a ventral view. The
photons emitted from the bioluminescent tumors or cells
were detected by the IVIS100 camera system, integrated,
digitized and displayed. Numbers of tumors per animal
were counted by eye from a dorsal and ventral view with
particular regard to the singular count of one metastatic
lesion.Immunohistochemistry
The following primary antibodies were used: Rabbit
polyclonal anti-phospho L-plastin antiserum (phospho
L-plastin) and mouse monoclonal anti-L-plastin antibody
(LPL4A.1). Isotype- and concentration matched control
antibodies (Dako, Hamburg, Germany) served as negative
controls.
Immunoenzyme staining was performed on 2-μm sec-
tions of formalin fixed, paraffin embedded murine organs.
Heat induced antigen-retrieval was achieved by incubat-
ing the slides in a steam cooker for 5 minutes in citrate
buffer, pH 6.1. Slides were further processed using the
standard avidin-biotin-complex anti-alkaline phosphat-
ase procedure (Vectorlabs, Burlingame, CA, USA) ac-
cording to the manufacturer’s instructions. The primary
antibody was added for 1 hour at 37°C. A donkey anti-
rabbit biotinylated antibody, 1/100 (Dako), was used as
a secondary reagent (30 min at room temperature).
Naphthol AS-biphosphate (Sigma, St. Louis, MO, USA)
with New-fuchsin (Merck, Darmstadt, Germany) served
as the substrate for alkaline phosphatase.Statistical methods
Statistical analyses were performed with GraphPad Prism
4.0. Data are shown as means ± SEM. Comparisons of
means were performed with two-tailed students t-test or
one-way ANOVA test, respectively. P values were consid-
ered significant when p < 0.05.Additional files
Additional file 1: Figure S1. Bioluminescent activity of tumor cells was
not influenced by transfection of the cells. (A) Bioluminescence imaging
of PC-3Mpro4/luc (PC3M) cells in vitro. (B) Bioluminescence imaging of
MV3 cells in vitro. The color bar at the right indicates the signal intensity
range (p/s/cm2/sr).
Additional file 2: Figure S2. S5A-LPL is not phosphorylated in PMA
treated MV3 cells as detected by native gel electrophoresis. A) LPL
phosphorylation can be detected by native gel electrophoresis followed
by Western blotting. LPL is known to be phosphorylated following PMA
stimulation of T-cells [18]. This phosphorylation can be visulized by
resolving proteins of untreated or PMA-treated T-cells (10-8 M; 30 min) on
native PAGE and staining of L-plastin on the corresponding Western blot
with L-plastin antibodies. In contrast to the situation with control cells,
PMA-treatment leads to the occurrence of a second band. This band
disappears if lysates from PMA stimulated cells were treated with alkaline
phosphatase (AP). B) For an unbiased analysis of LPL phosphorylation in
MV3 cells, lysates of control or PMA-treated MV3 cells expressing either
wt LPL or S5A LPL were subjected to native gel electrophoresis as
described in A. Only wt LPL, but not S5A-LPL showed a band shift after
PMA treatment of the cells, which demonstrates that S5A-LPL is not
phosphorylated.
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